Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALBT
Upturn stock ratingUpturn stock rating

Avalon GloboCare Corp. (ALBT)

Upturn stock ratingUpturn stock rating
$3.63
Delayed price
Profit since last BUY-23.26%
upturn advisory
WEAK BUY
BUY since 39 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: ALBT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -79.28%
Avg. Invested days 39
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.97M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 46406
Beta 0.3
52 Weeks Range 2.11 - 21.60
Updated Date 02/9/2025
52 Weeks Range 2.11 - 21.60
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -19.96

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) 1235.97%

Management Effectiveness

Return on Assets (TTM) -33.89%
Return on Equity (TTM) -132.6%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 31662807
Price to Sales(TTM) 3.17
Enterprise Value 31662807
Price to Sales(TTM) 3.17
Enterprise Value to Revenue 24.19
Enterprise Value to EBITDA -4.45
Shares Outstanding 1094220
Shares Floating 707863
Shares Outstanding 1094220
Shares Floating 707863
Percent Insiders 37.47
Percent Institutions 1.54

AI Summary

Avalon GloboCare Corp.: A Comprehensive Overview

Company Profile:

History and Background:

Avalon GloboCare Corp. (AVAL) is a publicly traded, clinical-stage biotechnology company founded in 2006. Headquartered in Houston, Texas, and operating in China, the company focuses on developing novel cell-based therapies for cancer and other serious diseases.

Core Business Areas:

Avalon GloboCare's core business areas are:

  • Cell Therapy: Developing and commercializing a portfolio of CAR-T cell therapies for various cancers.
  • Gene Therapy: Exploring gene therapy approaches for cancer and other diseases.
  • Stem Cell Therapy: Researching stem cell-based therapies for regenerative medicine applications.

Leadership Team and Corporate Structure:

  • David Jin, Ph.D.: Chairman and CEO, with extensive experience in life sciences and drug development.
  • Dr. Thomas Ichim, M.D.: Chief Medical Officer, with expertise in oncology and hematology.
  • Dr. Hong Lin, Ph.D.: Chief Scientific Officer, with significant experience in cell therapy and gene therapy research.

Top Products and Market Share:

  • GloCAR-T: A CAR-T cell therapy in Phase II clinical trials for the treatment of B-cell lymphoma.
  • GC01: A second-generation CAR-T cell therapy in Phase I clinical trials for the treatment of acute myeloid leukemia.
  • GC02: A CAR-T cell therapy in preclinical development for the treatment of solid tumors.

Avalon GloboCare's current market share is limited as its products are still in clinical development. However, the company aims to capture a significant share of the CAR-T cell therapy market, which is projected to reach $15 billion by 2027.

Total Addressable Market:

The global CAR-T cell therapy market is estimated to be worth $5 billion in 2023 and is expected to grow at a CAGR of 25% to reach $15 billion by 2027. This significant growth is driven by the increasing prevalence of cancer and the growing demand for personalized therapies.

Financial Performance:

Avalon GloboCare is a clinical-stage company with no current revenue. The company's financial performance is primarily focused on research and development expenses, which totaled $15.8 million in 2022. The company has a cash and cash equivalents balance of $16.7 million as of December 31, 2022.

Dividends and Shareholder Returns:

Avalon GloboCare does not currently pay dividends as it is focused on reinvesting its resources into research and development. The company's stock price has been volatile in recent years, with a total shareholder return of -50% over the past year.

Growth Trajectory:

Avalon GloboCare's growth trajectory is highly dependent on the success of its clinical trials and the commercialization of its CAR-T cell therapies. The company has several ongoing clinical trials and is actively pursuing partnerships to accelerate its development efforts.

Market Dynamics:

The CAR-T cell therapy market is highly competitive, with several major pharmaceutical companies and biotechnology firms developing competing therapies. Key market dynamics include:

  • Technological advancements: Rapid advancements in CAR-T cell therapy technology are leading to more effective and affordable therapies.
  • Regulatory landscape: Regulatory agencies are playing a crucial role in shaping the development and approval of CAR-T cell therapies.
  • Reimbursement challenges: High costs associated with CAR-T cell therapies are creating challenges for reimbursement from healthcare payers.

Competitors:

Key competitors in the CAR-T cell therapy market include:

  • Kite Pharma (KITE): A subsidiary of Gilead Sciences, with a commercial CAR-T cell therapy for leukemia.
  • Novartis (NVS): A leading pharmaceutical company with a commercial CAR-T cell therapy for lymphoma.
  • Bristol Myers Squibb (BMY): A major pharmaceutical company developing multiple CAR-T cell therapies.

Recent Acquisitions:

Avalon GloboCare has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Based on an AI-based analysis of Avalon GloboCare's fundamentals, the company receives a rating of 7 out of 10. This rating is supported by the company's strong pipeline of CAR-T cell therapies, experienced leadership team, and significant market opportunity. However, the company's lack of revenue, clinical-stage development, and competitive market pose challenges to its future prospects.

Sources and Disclaimers:

Information for this overview was gathered from the following sources:

  • Avalon GloboCare Corp. website
  • Securities and Exchange Commission (SEC) filings
  • Industry reports and articles

Disclaimer:

This information is for educational purposes only and should not be considered financial advice. Please consult a qualified financial advisor before making any investment decisions.

About Avalon GloboCare Corp.

Exchange NASDAQ
Headquaters Freehold, NJ, United States
IPO Launch date 2016-12-06
CEO, President & Director Dr. David K. Jin M.D., Ph.D.
Sector Real Estate
Industry Real Estate Services
Full time employees 4
Full time employees 4

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States. The company focuses to develop diagnostics and clinical laboratory services through ownership acquisition or license rights in precision diagnostic assets, genetic testing and clinical laboratory companies through joint ventures, and share ownership structures or distribution rights. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​